Aaron Seth Kesselheim

Aaron Seth Kesselheim, MD, JD, MPH

Professor of Medicine
Member, HMS Center for Bioethics

Aaron S. Kesselheim, MD, JD, MPH, is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Dr. Kesselheim received his medical and legal training at the University of Pennsylvania and his M.P.H. at the Harvard School of Public Health. Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. At the HMS Center for Bioethics, he co-teaches a course on health policy, law, and bioethics and organizes the monthly policy and ethics consortium.

Publications View
Major Events in the Life Course of New Drugs, 2000-2016.
Authors: Authors: Beall RF, Hwang TJ, Kesselheim AS.
N Engl J Med
View full abstract on Pubmed
Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
Authors: Authors: Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ.
PLoS Med
View full abstract on Pubmed
Approximating Future Generic Entry for New Drugs.
Authors: Authors: Beall RF, Darrow JJ, Kesselheim AS.
J Law Med Ethics
View full abstract on Pubmed
A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications.
Authors: Authors: Sarpatwari A, Gagne JJ, Lu Z, Campbell EG, Carman WJ, Enger CL, Dutcher SK, Jiang W, Kesselheim AS.
J Gen Intern Med
View full abstract on Pubmed
The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.
Authors: Authors: Darrow JJ, Beall RF, Kesselheim AS.
Appl Health Econ Health Policy
View full abstract on Pubmed
Internal Medicine Physicians' Financial Relationships with Industry: An Updated National Estimate.
Authors: Authors: Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM.
J Gen Intern Med
View full abstract on Pubmed
Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.
Authors: Authors: Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS.
Health Aff (Millwood)
View full abstract on Pubmed
An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?
Authors: Authors: Minssen T, Kesselheim AS, Darrow JJ.
Nat Biotechnol
View full abstract on Pubmed
Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Authors: Authors: Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, Fischer MA, Gagne JJ, Connolly JG.
Drug Saf
View full abstract on Pubmed
Changes in Drug Pricing After Drug Shortages in the United States.
Authors: Authors: Hernandez I, Sampathkumar S, Good CB, Kesselheim AS, Shrank WH.
Ann Intern Med
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
Boston, MA 02120